The Mutational, Prognostic, and Therapeutic Landscape of Neuroendocrine Neoplasms
The Oncologist · 2023
DOI: 10.1093/oncolo/oyad093 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Oncologist, 2023. Verfasst von Man Liu und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, People's Republic of China. Hauptthemen laut MEDLINE: Neuroendocrine Tumors, Carcinoma, Neuroendocrine, Pancreatic Neoplasms. Die Arbeit wurde bisher 25-mal zitiert (Crossref) und nennt 54 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: National Natural Science Foundation of China, Natural Science Foundation of Guangdong Province.
Abstract (Originalsprache)
Background
Neuroendocrine neoplasms (NENs) represent clinically and genetically heterogeneous malignancies, thus a comprehensive understanding of underlying molecular characteristics, prognostic signatures, and potential therapeutic targets is urgently needed.
Methods
Next-generation sequencing (NGS) and immunohistochemistry were applied to acquire genomic and immune profiles of NENs from 47 patients.
Results
Difference was distinguished based on differentiation grade and primary localization. Poorly differentiated neuroendocrine carcinomas (NECs) and well-differentiated neuroendocrine tumors (NETs) harbored distinct molecular features; we observed that tumor mutational burden (TMB) and tumor neoantigen burden (TNB) were significantly higher in NECs versus NETs. Notably, we identified a 7-gene panel (MLH3, NACA, NOTCH1, NPAP1, RANBP17, TSC2, and ZFHX4) as a novel prognostic signature in NENs; patients who carried mutations in any of the 7 genes exhibited significantly poorer survival. Furthermore, loss of heterozygosity (LOH) and germline homogeneity in human leukocyte antigen (HLA) are common in NENs, accounting for 39% and 36%, respectively. Notably, HLA LOH was an important prognostic biomarker for a subgroup of NEN patients. Finally, we analyzed clinically actionable targets in NENs, revealing that TMB high (TMB-H) or gene mutations in TP53, KRAS, and HRAS were the most frequently observed therapeutic indicators, which granted eligibility to immune checkpoint blockade (ICB) and targeted therapy.
Conclusion
Our study revealed heterogeneity of NENs, and identified novel prognostic signatures and potential therapeutic targets, which directing improvements of clinical management for NEN patients in the foreseeable future.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Gastroenterology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, People's Republic of China.
- Department of Translational Medicine, YuceBio Technology Co., Ltd, Shenzhen, People's Republic of China.
- Department of Medicine, YuceBio Technology Co., Ltd, Shenzhen, People's Republic of China.
- Department of Gastroenterology, Digestive Disease Hospital, Affiliated Hospital of Zunyi Medical University, Zunyi, People's Republic of China.
- Department of Interventional Oncology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, People's Republic of China.
- Department of Pathology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, People's Republic of China.
Förderung
- National Natural Science Foundation of China
- Natural Science Foundation of Guangdong Province
Zitieren
APA
Liu, M., Li, N., Tang, H., Chen, L., Liu, X., Wang, Y., Lin, Y., Luo, Y., Wei, S., Wen, W., Chen, M., Wang, J., Zhang, N., & Chen, J. (2023). The Mutational, Prognostic, and Therapeutic Landscape of Neuroendocrine Neoplasms. The Oncologist. https://doi.org/10.1093/oncolo/oyad093
Vancouver
Liu M, Li N, Tang H, Chen L, Liu X, Wang Y, et al. The Mutational, Prognostic, and Therapeutic Landscape of Neuroendocrine Neoplasms. The Oncologist. 2023. doi:10.1093/oncolo/oyad093
BibTeX
@article{Liu2023,
author = {Liu, Man and Li, Na and Tang, Hongzhen and Chen, Luohai and Liu, Xuemei and Wang, Yu and Lin, Yuan and Luo, Yanji and Wei, Shaozhen and Wen, Wenli and Chen, Minhu and Wang, Jiaqian and Zhang, Ning and Chen, Jie},
title = {The Mutational, Prognostic, and Therapeutic Landscape of Neuroendocrine Neoplasms},
journal = {The Oncologist},
year = {2023},
doi = {10.1093/oncolo/oyad093}
}
EUVIMED